Ahn Y et al., 2014. The ketogenic diet modifies social and metabolic alterations identified in the prenatal valproic acid model of autism spectrum disorder. Dev Neurosci. 36(5):371-80. doi: 10.1159/000362645.

Amiet C et al., 2014. Are there cultural differences in parental interest in early diagnosis and genetic risk assessment for autism spectrum disorder? Front Pediatr. 2:32. doi: 10.3389/fped.2014.00032.

Auyeung B et al., 2015. Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Transl Psychiatry. 5:e507. doi: 10.1038/tp.2014.146.

Avella-Garcia CB et al., 2016. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. Int J Epidemiol. Jun 28. pii: dyw115.

Barua S 2015. High gestational folic acid supplementation alters expression of imprinted and candidate autism susceptibility genes in a sex-specific manner in mouse offspring. J Mol Neurosci. 58(2):277-86. doi: 10.1007/s12031-015-0673-8.

Bradstreet JJ et al., 2010. Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Altern Med Rev. 15(1):15-32.

Brandenburg LO et al., 2010. Sulforaphane suppresses LPS-induced inflammation in primary rat microglia. Inflamm Res. 59(6):443-50. doi: 10.1007/s00011-009-0116-5.

Burrows EL et al., 2015. A neuroligin-3 mutation implicated in autism causes abnormal aggression and increases repetitive behavior in mice. Mol Autism. 14:6:62.

Chen PS, 2006. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry. 11(12):1116-25.

Chen PS et al., 2007. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 149(1):203-12.

Chez MG et al., 2004. Memantine as add-on therapy in pediatric epileptic patients: Effects on cognitive development and seizure frequency. Epilepsia. 45(Suppl. 7):152.

Chez MG et al. 2007. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 22(5):574-9.

Dragunow M et al., 2006. Valproic acid induces caspase 3-mediated apoptosis in microglial cells. Neuroscience. 140(4):1149-56.

Erickson CA et al. 2009. Open-label memantine in fragile X syndrome. J Autism Dev Disord. 39(12):1629-35.

Faber S. et al., 2015. b. A cleanroom sleeping environment’s impact on markers of oxidative stress, immune dysregulation, and behavior in children with autism spectrum disorders. BMC Complement Altern Med. 2015; 15: 71. doi: 10.1186/s12906-015-0564-0

Feng J et al., 2016. Clinical improvement following vitamin D₃ supplementation in Autism Spectrum Disorder. Nutr Neurosci. 2016 Jan 18. [Epub ahead of print] doi: 10.1080/1028415X.2015.1123847

Frühauf PK et al., 2015. Spermine reverses lipopolysaccharide-induced memory deficit in mice. J Neuroinflammation. 12:3. doi: 10.1186/s12974-014-0220-5.

Frye RE et al., 2010. Tetrahydrobiopterin as a novel therapeutic intervention for autism. Neurotherapeutics. 7(3):241-9. doi: 10.1016/j.nurt.2010.05.004.

Frye RE, Rossignol DA 2014. Treatments for biomedical abnormalities associated with autism spectrum disorder. Front Pediatr. 2:66. doi: 10.3389/fped.2014.00066.

Gozes I. 2015. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. Biol Chem. pii: /j/bchm.ahead-of-print/hsz-2015-0152/hsz-2015-0152.xml. doi: 10.1515/hsz-2015-0152.

Gozes I et al.,2011. Microtubules, schizophrenia and cognitive behavior: Preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides. 32:428–431.

Handrigan GR. 2013. Deletions in 16q24.2 are associated with autism spectrum disorder, intellectual disability and congenital renal malformation. J Med Genet. 50(3):163-73. doi: 10.1136/jmedgenet-2012-101288.

Hultman CM et al., 2011. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry. 16(12):1203-12. doi: 10.1038/mp.2010.121.

Kanne SM et al., 2011. The role of adaptive behavior in autism spectrum disorders: implications for functional outcome. J Autism Dev Disord. 41(8):1007-18. doi: 10.1007/s10803-010-1126-4.

Klaiman C et al., 2013. Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 23(5):320-8. doi: 10.1089/cap.2012.0127.

Kloss CU et al., 1997. Proliferation of ramified microglia on an astrocyte monolayer: characterization of stimulatory and inhibitory cytokines. J Neurosci Res. 49(2):248-54.

Lai MC et al., 2014. Autism. Lancet. 383(9920):896-910. doi: 10.1016/S0140-6736(13)61539-1.

Lee JC and JB Tomblin. 2012. Reinforcement learning in young adults with developmental language impairment. Brain Lang. 123(3):154-63. doi: 10.1016/j.bandl.2012.07.009.

May ME et al., 2012. Moderating effects of autism on parent views of genetic screening for aggression. Intellect Dev Disabil. 50(5):415-25. doi: 10.1352/1934-9556-50.5.415.

Napoli E et al., 2014. Potential therapeutic use of the ketogenic diet in autism spectrum disorders. Front Pediatr. 2:69. doi: 10.3389/fped.2014.00069.

Pagan C et al., 2014. The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders. Transl Psychiatry. 4:e479. doi: 10.1038/tp.2014.120.

Rosi S et al., 2006. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 142(4):1303–15. doi:10.1016/j.neuroscience.2006.08.017.

Ruskin DN et al., 2013. Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One. 8(6):e65021. doi: 10.1371/journal.pone.0065021.

Segura M et al., 2015 Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder. Neurogenetics. 16(2):123-31. doi: 10.1007/s10048-014-0434-9.

Singh K et al., 2014. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 111(43):15550-5. doi: 10.1073/pnas.1416940111.

Suda S et al., 2013. Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur J Pharmacol 707(1-3):26-31. doi: 10.1016/j.ejphar.2013.03.020.

Surén P et al., 2013. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA. 309(6):570-7. doi: 10.1001/jama.2012.155925.

Stutzman D and J Dopheide. 2015. Acetylcysteine for treatment of autism spectrum disorder symptoms. Am J Health Syst Pharm. 72(22):1956-9. doi: 10.2146/ajhp150072.

Takesada M et al., 1990. An open clinical study of aprpterin hydrochloride(R-tetrahydrobiopterin, R-THBP) in infantile autism – clinical effects and long-term follow-up. International Symposium on Neurobiology of Infantile Autism; Tokyo, Japan. 1990.

Tsilioni I et al., 2015. Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6. Transl Psychiatry. 5:e647. doi: 10.1038/tp.2015.142.

Vulih-Shultzman I, et al., 2007. Activity dependent neuroprotective protein snippet NAP reduces tau hyper-phosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 323:438–449.

Wei H et al. 2012. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS One. 7(5):e36981. doi: 10.1371/journal.pone.0036981.

Wu HM et al., 2009. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology. 34(10):2344-57. doi: 10.1038/npp.2009.64.

Xuan A et al., 2012. Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci. 90(11-12):463-8. doi: 10.1016/j.lfs.2012.01.001.

Zhang XY et al., 2015. Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice. J Neuroinflammation.;12:20. doi: 10.1186/s12974-015-0238-3.

• Uncategorized